This week's update on the Philadelphia-area life sciences industry includes news on a multimillion-dollar knee pain product deal, a potential new chronic sinusitis treatment, a medical technology approval, and more.
Here's the roundup:
The specialty pharmaceutical company that has its U.S. headquarters in Malvern said its subsidiary Endo Ventures Ltd. has reached an agreement to commercialize a Japanese company's experimental osteoarthritis knee pain drug in the United States — should it receive…
